Thursday, Soligenix, Inc. (SNGX) announced that the FDA has given orphan drug status for the active component in SuVax, a subunit protein vaccine created to prevent and provide post-exposure prophylaxis against Sudan ebolavirus infection.
Oreola Donini, chief scientific officer at Soligenix, pointed out the vaccines' 100 protection rate in studies on non-human primates. SuVax has also demonstrated stability for a minimum of two years at temperatures as high as 40 degrees Celsius.
If approved by the FDA, this designation would secure SuVax with seven years of exclusive market rights in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.